Black Diamond Therapeutics Inc. Common Stock (BDTX)

About BDTX

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

21

Website

www.blackdiamondtherapeutics.com/

Fundamentals

1-day range

$2.08$2.21

Market cap

$110.02M

P/E (trailing)

—

P/E (forward)

-2.19

EPS (trailing)

$-0.76

Dividend yield

—

Beta

3.29

Avg. volume

1.63M

Forecasts

7 analyst ratings

Black Diamond Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BDTX

  Black Diamond Therapeutics Inc. Common Stock

  $2.23

  ▼ 1.76%
  Market cap $110.02MP/E —
  $1.6$4.94
• PTHS

  Pelthos Therapeutics Inc. Common Stock

  $24.46

  ▼ 2.16%
  Market cap $102.36MP/E —
  $18.19$37.5
• CGTX

  Cognition Therapeutics Inc. Common Stock

  $1.03

  ▼ 3.30%
  Market cap $101.13MP/E —
  $0.5501$2.79
• KLRS

  Kalaris Therapeutics Inc. Common Stock

  $4.03

  ▼ 1.71%
  Market cap $99.69MP/E —
  $3.03$11.88
• ENGN

  enGene Therapeutics Inc. Common Stock

  $1.83

  ▼ 4.19%
  Market cap $120.58MP/E —
  $1.4$12.25
• ATRA

  Atara Biotherapeutics Inc. Common Stock

  $9.16

  ▼ 0.97%
  Market cap $74.33MP/E —
  $3.92$19.15
• ELOX

  Eloxx Pharmaceuticals Inc. Common Stock

  $15.07

  ▼ 12.69%
  Market cap $71.48MP/E —
  $0$23.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
  Benzinga · 8/5/2026

• Prakash Raman · June 19, 2026 · Grant

  7.9K @ $1.66
• Ali Behbahani · June 19, 2026 · Grant

  9.0K @ $1.66
• Prakash Raman · March 20, 2026 · Grant

  6.1K @ $2.15
• Ali Behbahani · March 20, 2026 · Grant

  6.9K @ $2.15

Institutional Ownership

March 31, 2026

Total shares held

36.81M

Total value held

$50.55M

Institutional holders

101